Experienced in Chronic Demyelinizing Neuropathy with IgM Monoclonal

Dr. Craig Zaidman

Neurology
Washington University
660 S Euclid Ave, 
Saint Louis, MO 
Experienced in Chronic Demyelinizing Neuropathy with IgM Monoclonal
Washington University
660 S Euclid Ave, 
Saint Louis, MO 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Craig Zaidman is a Neurologist in Saint Louis, Missouri. Dr. Zaidman is rated as an Experienced provider by MediFind in the treatment of Chronic Demyelinizing Neuropathy with IgM Monoclonal. His top areas of expertise are Becker Muscular Dystrophy, Duchenne Muscular Dystrophy, Spinal Muscular Atrophy (SMA), and Primary Lateral Sclerosis.

His clinical research consists of co-authoring 77 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Chronic Demyelinizing Neuropathy with IgM Monoclonal.

Specialties
Neurology
Licenses
Neurology with Special Qualifications in Neurology in MO
Hospital Affiliations
St Louis Childrens Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Buckeye Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
Cigna
  • EPO
  • HMO
  • PPO
Cox Health
  • EPO
  • PPO
Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 7 Less Insurance Carriers -

Locations

Washington University
660 S Euclid Ave, Saint Louis, MO 63110
Other Locations
Office
1 Childrens Pl Ste 2D, Saint Louis,, MO 63110

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

An Open-Label, Systemic Gene Delivery Study Using Commercial Process Material to Evaluate the Safety of and Expression From SRP-9001 in Subjects With Duchenne Muscular Dystrophy (ENDEAVOR)
An Open-Label, Systemic Gene Delivery Study Using Commercial Process Material to Evaluate the Safety of and Expression From SRP-9001 in Subjects With Duchenne Muscular Dystrophy (ENDEAVOR)
Enrollment Status: Active_not_recruiting
Publish Date: August 11, 2025
Intervention Type: Genetic
Study Phase: Phase 1
A Phase 3 Multinational, Randomized, Double-Blind, Placebo-Controlled Systemic Gene Delivery Study to Evaluate the Safety and Efficacy of SRP-9001 in Subjects With Duchenne Muscular Dystrophy (EMBARK)
A Phase 3 Multinational, Randomized, Double-Blind, Placebo-Controlled Systemic Gene Delivery Study to Evaluate the Safety and Efficacy of SRP-9001 in Subjects With Duchenne Muscular Dystrophy (EMBARK)
Enrollment Status: Completed
Publish Date: July 08, 2025
Intervention Type: Genetic
Study Phase: Phase 3
Open Label, Long-term Safety, Tolerability, and Efficacy Study of GIVINOSTAT in All DMD Patients Who Have Been Previously Treated in One of the GIVINOSTAT Studies
Open Label, Long-term Safety, Tolerability, and Efficacy Study of GIVINOSTAT in All DMD Patients Who Have Been Previously Treated in One of the GIVINOSTAT Studies
Enrollment Status: Active_not_recruiting
Publish Date: April 30, 2025
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study With an Open-Label Extension to Determine the Safety, Pharmacokinetics and Efficacy of Oral Ifetroban in Subjects With Duchenne Muscular Dystrophy
A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study With an Open-Label Extension to Determine the Safety, Pharmacokinetics and Efficacy of Oral Ifetroban in Subjects With Duchenne Muscular Dystrophy
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2025
Intervention Type: Drug
Study Drug: Ifetroban
Study Phase: Phase 2
A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Ambulatory Subjects With Duchenne Muscular Dystrophy (DMD)
A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Ambulatory Subjects With Duchenne Muscular Dystrophy (DMD)
Enrollment Status: Terminated
Publish Date: August 26, 2024
Intervention Type: Drug
Study Drug: Pamrevlumab
Study Phase: Phase 3
A Phase 3, Randomized, Double-Blind Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Subjects With Non-ambulatory Duchenne Muscular Dystrophy (DMD)
A Phase 3, Randomized, Double-Blind Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Subjects With Non-ambulatory Duchenne Muscular Dystrophy (DMD)
Enrollment Status: Terminated
Publish Date: March 12, 2024
Intervention Type: Drug
Study Drug: Pamrevlumab
Study Phase: Phase 3
Phase I, Open-Label, Dose Comparison Study of AVXS-101 for Sitting But Non-ambulatory Patients With Spinal Muscular Atrophy
Phase I, Open-Label, Dose Comparison Study of AVXS-101 for Sitting But Non-ambulatory Patients With Spinal Muscular Atrophy
Enrollment Status: Terminated
Publish Date: April 24, 2023
Intervention Type: Biological
Study Phase: Phase 1
Randomised, Double Blind, Placebo Controlled, Multicentre Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Duchenne Muscular Dystrophy
Randomised, Double Blind, Placebo Controlled, Multicentre Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Duchenne Muscular Dystrophy
Enrollment Status: Completed
Publish Date: February 02, 2023
Intervention Type: Drug
Study Drug: Givinostat
Study Phase: Phase 3
A Global Study of a Single, One-Time Dose of AVXS-101 Delivered to Infants With Genetically Diagnosed and Pre-symptomatic Spinal Muscular Atrophy With Multiple Copies of SMN2
A Global Study of a Single, One-Time Dose of AVXS-101 Delivered to Infants With Genetically Diagnosed and Pre-symptomatic Spinal Muscular Atrophy With Multiple Copies of SMN2
Enrollment Status: Completed
Publish Date: September 07, 2022
Intervention Type: Biological
Study Drug: Onasemnogene Abeparvovec-Xioi
Study Phase: Phase 3
View 8 Less Clinical Trials

77 Total Publications

Consensus recommendations and considerations for the delivery and monitoring of gene therapy in patients with Duchenne muscular dystrophy.
Consensus recommendations and considerations for the delivery and monitoring of gene therapy in patients with Duchenne muscular dystrophy.
Journal: Neuromuscular disorders : NMD
Published: June 17, 2025
Similar Doctors
Alan Pestronk
Advanced in Chronic Demyelinizing Neuropathy with IgM Monoclonal
Dr. Alan Pestronk
Neurology
Advanced in Chronic Demyelinizing Neuropathy with IgM Monoclonal
Dr. Alan Pestronk
Neurology

Center For Advanced Medicine

4921 Parkview Place, Suite 6C, 
Saint Louis, MO 
 (0.2 miles away)
314-747-1005
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Alan Pestronk is a Neurologist in Saint Louis, Missouri. Dr. Pestronk is rated as a Distinguished provider by MediFind in the treatment of Chronic Demyelinizing Neuropathy with IgM Monoclonal. His top areas of expertise are Dysferlinopathy, Miyoshi Myopathy, Pompe Disease, and Myasthenia Gravis. Dr. Pestronk is currently accepting new patients.

Advanced in Chronic Demyelinizing Neuropathy with IgM Monoclonal
Dr. Zaheer Ahmed
Neurology
Advanced in Chronic Demyelinizing Neuropathy with IgM Monoclonal
Dr. Zaheer Ahmed
Neurology

St. Luke's Neurology - DOC B

111 Saint Lukes Center Dr Ste 20, 
Chesterfield, MO 
 (14.7 miles away)
636-685-7745
Languages Spoken:
English
See accepted insurances

Zaheer Ahmed is a Neurologist in Chesterfield, Missouri. Dr. Ahmed is rated as a Distinguished provider by MediFind in the treatment of Chronic Demyelinizing Neuropathy with IgM Monoclonal. His top areas of expertise are Migraine, Chronic Inflammatory Demyelinating Polyneuropathy, Transient Ischemic Attack (TIA), and Memory Loss.

Advanced in Chronic Demyelinizing Neuropathy with IgM Monoclonal
Dr. Glenn Lopate
Neurology
Advanced in Chronic Demyelinizing Neuropathy with IgM Monoclonal
Dr. Glenn Lopate
Neurology
517 S Euclid Ave, Div Neurology Neuromuscular, G Fl, 
Saint Louis, MO 
 (0.2 miles away)
314-362-1408
Languages Spoken:
English

Glenn Lopate is a Neurologist in Saint Louis, Missouri. Dr. Lopate is rated as an Advanced provider by MediFind in the treatment of Chronic Demyelinizing Neuropathy with IgM Monoclonal. His top areas of expertise are Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Inclusion Body Myositis, Chronic Demyelinizing Neuropathy with IgM Monoclonal, and Peripheral Neuropathy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Zaidman's expertise for a condition
ConditionClose
View All 24 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile